Batu Biologics Completes Seed Round Financing

Batu Biologics Continues Fight in War Against Lung Cancer

Closure of $1 million seed round to support development of anti-angiogenic immune therapy, ValloVax™

Batu Biologics, an immuno-oncology company, has successfully completed its $1 million seed round of funding, bringing the company one step closer in its efforts to battle lung cancer, the leading cancer killer in the United States. Batu leveraged primarily private and angel funding to attain this fundraising goal.

Read the full article at businesswire.com

0